Evidence map›Paper›PMID 40207688›Full record

ArticleThe British journal of surgery2025

Impact of gross extrathyroidal extension to the recurrent laryngeal nerve alone on survival in papillary thyroid carcinoma.

Victoria Harries, Daniel W Scholfield, Alana Eagan, R Michael Tuttle, Ashok R Shaha, Jatin P Shah, Richard J Wong, Snehal G Patel, Ian Ganly

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Victoria HarriesDepartment of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Daniel W ScholfieldDepartment of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Alana EaganDepartment of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
R Michael TuttleDepartment of Medicine, Endocrine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ashok R ShahaDepartment of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jatin P ShahDepartment of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Richard J WongDepartment of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Snehal G PatelDepartment of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ian GanlyDepartment of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0001-7636-5426

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748NIH
6 · The paper itself

Abstract

backgroundGross extrathyroidal extension (ETE) is one of the most important predictors of survival in papillary thyroid carcinoma (PTC). The aim of this study is to determine the impact of gross ETE to the recurrent laryngeal nerve alone (RLNT4aETE) on survival.

methodsAfter institutional review board approval, adult PTC patients were identified from an institutional database undergoing initial surgery for well-differentiated thyroid carcinoma from 1986 to 2020. Patients were classified as having no gross ETE, gross ETE to strap muscles only (T3bETE), RLNT4aETE, or gross ETE involving other adjacent structures (otherT4aETE). Disease-specific survival (DSS) was calculated using the Kaplan-Meier method and groups were compared using the log-rank test.

resultsThere were 8030 patients included in the analysis; 7578 patients (94.2%) with no gross ETE, 197 (2.4%) with T3bETE, 40 (0.5%) with RLNT4aETE, and 215 (2.7%) with otherT4aETE. The estimated 10-year DSS for patients with no gross ETE, T3bETE, RLNT4aETE, and otherT4aETE in the whole cohort were 99.2%, 95.7%, 96.9%, and 82.5% respectively (P < 0.0001). After controlling for age, nodal and distant disease stage, RLNT4aETE patients had a similar DSS to T3bETE patients, when compared to no gross ETE patients (HRs 2.91 versus 2.28 respectively). In the ≥55-year-old cohort, the 10-year DSS for patients with no gross ETE, T3bETE, RLNT4aETE, and otherT4aETE were 97.7%, 89.4%, 90.9% and 67.6% respectively.

conclusionRLNT4aETE patients appear to have a similar DSS to T3bETE patients. This highlights the heterogeneity within the current T4a cohort and supports the downstaging of RLNT4aETE patients to the T3b classification.

Indexed as

Recurrent Laryngeal NerveThyroid Cancer, PapillaryThyroid NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedNeoplasm InvasivenessRetrospective StudiesThyroidectomy

Identifiers

PMID40207688
PMCPMC12168062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.